Current and historical daily PE Ratio for Incyte Corp (
FRA:ICY
) from 1993 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Incyte stock (FRA:ICY) PE ratio as of Apr 25 2024 is 19.52.
More Details
Incyte Corp (FRA:ICY) PE Ratio (TTM) Chart
Incyte Corp (FRA:ICY) PE Ratio (TTM) Historical Data
View and export this data going back to 1993. Start your Free Trial
Total 1223
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Incyte PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-25 | 19.6 | 2024-02-20 | 21.8 |
| 2024-04-24 | 19.6 | 2024-02-19 | 21.9 |
| 2024-04-23 | 19.8 | 2024-02-16 | 22.4 |
| 2024-04-22 | 20.0 | 2024-02-15 | 22.0 |
| 2024-04-19 | 20.2 | 2024-02-14 | 22.3 |
| 2024-04-18 | 20.1 | 2024-02-13 | 22.2 |
| 2024-04-17 | 20.4 | 2024-02-12 | 21.8 |
| 2024-04-16 | 20.5 | 2024-02-09 | 21.6 |
| 2024-04-15 | 20.6 | 2024-02-08 | 21.6 |
| 2024-04-12 | 20.9 | 2024-02-07 | 22.5 |
| 2024-04-11 | 20.8 | 2024-02-06 | 22.4 |
| 2024-04-10 | 20.7 | 2024-02-05 | 22.0 |
| 2024-04-09 | 20.6 | 2024-02-02 | 22.1 |
| 2024-04-08 | 20.8 | 2024-02-01 | 22.1 |
| 2024-04-05 | 20.7 | 2024-01-31 | 22.2 |
| 2024-04-04 | 20.9 | 2024-01-30 | 22.7 |
| 2024-04-03 | 21.0 | 2024-01-29 | 22.7 |
| 2024-04-02 | 21.5 | 2024-01-26 | 22.8 |
| 2024-03-28 | 21.4 | 2024-01-25 | 22.8 |
| 2024-03-27 | 21.3 | 2024-01-24 | 23.1 |
| 2024-03-26 | 21.6 | 2024-01-23 | 22.9 |
| 2024-03-25 | 21.3 | 2024-01-22 | 23.1 |
| 2024-03-22 | 21.6 | 2024-01-19 | 22.9 |
| 2024-03-21 | 21.7 | 2024-01-18 | 23.2 |
| 2024-03-20 | 21.8 | 2024-01-17 | 22.8 |
| 2024-03-19 | 21.5 | 2024-01-16 | 23.4 |
| 2024-03-18 | 21.8 | 2024-01-12 | 23.4 |
| 2024-03-15 | 21.8 | 2024-01-11 | 23.8 |
| 2024-03-14 | 21.9 | 2024-01-10 | 23.9 |
| 2024-03-13 | 22.1 | 2024-01-09 | 24.4 |
| 2024-03-12 | 22.6 | 2024-01-08 | 24.3 |
| 2024-03-11 | 22.3 | 2024-01-05 | 24.8 |
| 2024-03-08 | 21.9 | 2024-01-04 | 24.1 |
| 2024-03-07 | 22.0 | 2024-01-03 | 24.7 |
| 2024-03-06 | 22.0 | 2024-01-02 | 23.2 |
| 2024-03-05 | 22.4 | 2023-12-29 | 23.1 |
| 2024-03-04 | 22.2 | 2023-12-28 | 22.9 |
| 2024-03-01 | 22.0 | 2023-12-27 | 32.2 |
| 2024-02-29 | 22.5 | 2023-12-22 | 31.7 |
| 2024-02-28 | 22.9 | 2023-12-21 | 31.5 |
| 2024-02-27 | 22.6 | 2023-12-20 | 32.0 |
| 2024-02-26 | 22.8 | 2023-12-19 | 31.7 |
| 2024-02-23 | 22.9 | 2023-12-18 | 32.4 |
| 2024-02-22 | 22.7 | 2023-12-15 | 33.0 |
| 2024-02-21 | 22.1 | 2023-12-14 | 33.4 |
Incyte Corp (FRA:ICY) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Incyte Corp
NAICS : 541714
SIC : 8731
ISIN : US45337C1027
Share Class Description:
FRA:ICY: Ordinary SharesCompare
Compare
Traded in other countries / regions
INCY.USAI1NC34.BrazilICY.Germany1INCY.ItalyINCY.MexicoINCY.Austria0J9P.UK IPO Date
1993-11-03Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers